DATE: June 23, 2021

TO: Knowledge Ecology International (KEI)
1621 Connecticut Ave NW
Washington, DC 20009
www.keionline.org

SUBJECT: KEI Comments regarding 86 FR 26927, “Prospective Grant of an Exclusive Patent License: Development, Commercialization, and Use of Protein-Based Vaccines Expressing Recombinant Measles and Mumps Immunogens for Human Use To Prevent Measles and/or Mumps Infections, Disease, and Transmission” notice – Prospective Exclusive Patent License to Mevox, Ltd.

Dear James Love:

Thank you for providing us with your comments regarding the notice of the proposed license the National Institute of Allergy and Infectious Diseases (NIAID) intends to grant to Mevox, Ltd.

Prior to posting a notice for a proposed grant of an exclusive license, the NIAID determines that the criteria set forth in 37 CFR 404 have been satisfied and that the company is qualified both technically and financially to be granted an exclusive license to the Government’s intellectual property in the fields of use as specified. The notice period provides an opportunity for public comment and possible objection to the proposed license. We will consider your comments.

Best regards,

Daniel Lee, J.D.
Technology Transfer and Patent Specialist
Technology Transfer and Intellectual Property Office
National Institute of Allergy and Infectious Diseases
5601 Fisher Lane, Suite 6D
Rockville, MD 20892-9804

Digitally signed by Daniel D. Lee
Date: 2021.06.23 10:47:02 -04'00'